TDM SLE01
Alternative Names: TDM-SLE01Latest Information Update: 06 Mar 2024
Price :
$50 *
At a glance
- Originator TechnoDerma Medicines
- Class Skin disorder therapies; Small molecules
- Mechanism of Action TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Systemic lupus erythematosus
Most Recent Events
- 05 Mar 2024 Preclinical trials in Systemic lupus erythematosus in China (unspecified route) (TechnoDerma Medicines pipeline, March 2024)
- 05 Mar 2024 TechnoDerma Medicines plans to file an IND application in fourth quarter of 2024 (TechnoDerma Medicines pipeline, March 2024)
- 30 Aug 2021 Early research in Systemic lupus erythematosus in China (unspecified route) prior to August 2021 (TechnoDerma Medicines pipeline, August 2021)